On Dec. 21, CMS published a Final Rule to support state flexibility to enter into value-based purchasing arrangements (VBPs) with drug manufacturers, and to allow manufacturers with qualifying VBPs to report multiple best price points for a single dosage form and strength of a covered outpatient drug. The final rule is effective on Jan. 1, 2022.
This timeline documenting the history of the Journal of Managed Care + Specialty Pharmacy was developed as part of efforts commemorating the 25th anniversary of the journal in 2020.
Last week, more than 30 experts representing payers, pharmacists, integrated delivery systems, health economists and analysts, patient advocates, academicians, pharmaceutical manufacturers, and other key decision-makers in the managed care setting convened virtually for AMCP’s Partnership Forum “Biosimilars: Policy, Practice, and Post-Marketing Surveillance to Support Treatment and Coverage Decisions” to identify key actions that support the use and development of biosimilars in the U.S. health care system.
Partnership Forum: The market for biologic drugs in the United States is large and has the potential to play an increasingly important role in the country’s health care system — both in the treatment of disease and in the affordability of drugs. Biosimilar approval and marketing of products in the United States is at a slower pace than desired by many stakeholders. This forum helped identify key actions that could support the further development and use of biologics in the U.S. health care system.
AMCP Signs Letter Urging Funds for COVID Vaccine Administration; FDA Recommends EUA for Pfizer-BioNTech COVID-19 Vaccine; CDC Interim Recommendations for Allocating Initial COVID-19 Vaccine; SCOTUS Ruling on Rutledge v. PCMA; AMCP Summary of Medicare Part B MFN Model; AMCP Summary of Medicare Part D Rebate Rule; AMCP Comments on CMS Draft Guidance for CY 2022 Medicare Advantage Capitation Rates, Part C and Part D Payment Policies; Electoral College Formally Designates Joe Biden President-Elect.
On Dec. 12, AMCP joined the Pharmacy Supply and Payment Chain Coalition's letter to Congressional leaders urging them to support the CDC's request for supplemental funding to cover the cost of administering COVID-19 vaccines.
The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration’s approval of the first Emergency Use Authorization for the COVID-19 vaccine.
